Security key
98943L107
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)
CUSIP: 98943L107
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Shares outstanding
- 72,096,078
- Total 13F shares
- 76,565,937
- Share change
- -8,743,532
- Total reported value
- $313,165,477
- Put/Call ratio
- 11%
- Price per share
- $4.09
- Number of holders
- 142
- Value change
- -$54,359,485
- Number of buys
- 78
- Number of sells
- 64
Report period
Q2 2024
Institutions
142
Top holders
10
ZNTL full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Zentalis Pharmaceuticals, Inc. SEC filings
Zentalis Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98943L107
Recent filing periods:
Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP |
13F
|
Company |
19%
|
13,959,973
|
$220,009,174 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
16%
|
11,574,821
|
$182,419,179 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
15%
|
10,644,024
|
$167,749,818 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
6.4%
|
4,645,758
|
$73,217,147 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.1%
|
4,398,625
|
$69,322,330 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
5.3%
|
3,852,429
|
$60,714,281 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
5.3%
|
3,785,652
|
$59,661,876 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
4.8%
|
3,489,709
|
$54,999,000 | — | 31 Mar 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
4.6%
|
3,319,086
|
$52,309,000 | — | 31 Mar 2024 | |
| Capital International Investors |
13F
|
Company |
3.9%
|
2,819,664
|
$44,437,905 | — | 31 Mar 2024 | |
| Decheng Capital LLC |
13F
|
Company |
2.9%
|
2,099,583
|
$33,089,429 | — | 31 Mar 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.8%
|
1,998,700
|
$31,499,512 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
2.1%
|
1,516,183
|
$23,895,044 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
2%
|
1,437,026
|
$22,647,530 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,302,237
|
$20,525,898 | — | 31 Mar 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
1.6%
|
1,164,610
|
$18,354,254 | — | 31 Mar 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
1.6%
|
1,155,236
|
$18,206,519 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
1,037,409
|
$16,349,566 | — | 31 Mar 2024 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.3%
|
961,486
|
$15,153,020 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.3%
|
944,917
|
$14,891,892 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1%
|
723,656
|
$11,404,819 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.73%
|
523,702
|
$8,253,545 | — | 31 Mar 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.68%
|
490,000
|
$7,722,400 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.66%
|
475,956
|
$7,501,066 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.63%
|
455,937
|
$7,185,567 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
0.62%
|
450,000
|
$7,092,000 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.46%
|
332,000
|
$5,232,320 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.41%
|
298,008
|
$4,696,606 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.4%
|
289,880
|
$4,568,509 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.37%
|
267,865
|
$4,221,552 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.36%
|
261,937
|
$4,128,000 | — | 31 Mar 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.36%
|
258,818
|
$4,078,972 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.36%
|
257,087
|
$4,051,691 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.34%
|
246,322
|
$3,882,035 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.34%
|
244,995
|
$3,861,121 | — | 31 Mar 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
0.28%
|
200,000
|
$3,152,000 | — | 31 Mar 2024 | |
| Mayo Clinic |
13F
|
Company |
0.26%
|
187,143
|
$2,949,374 | — | 31 Mar 2024 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.2%
|
144,623
|
$2,279,259 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
0.2%
|
142,956
|
$2,252,987 | — | 31 Mar 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.18%
|
131,815
|
$2,077,404 | — | 31 Mar 2024 | |
| PDT Partners, LLC |
13F
|
Company |
0.18%
|
131,263
|
$2,068,705 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.18%
|
130,308
|
$2,053,655 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.17%
|
124,287
|
$1,958,763 | — | 31 Mar 2024 | |
| Jump Financial, LLC |
13F
|
Company |
0.16%
|
118,648
|
$1,869,893 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.16%
|
113,750
|
$1,792,000 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.14%
|
101,000
|
$1,591,760 | — | 31 Mar 2024 | |
| Swiss National Bank |
13F
|
Company |
0.14%
|
97,400
|
$1,535,024 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.12%
|
89,012
|
$1,402,829 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.11%
|
82,762
|
$1,304,316 | — | 31 Mar 2024 | |
| Values First Advisors, Inc. |
13F
|
Company |
0.1%
|
71,066
|
$1,119,997 | — | 31 Mar 2024 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q2 2024
As of 30 Jun 2024,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,565,937 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, FMR LLC, EVENTIDE ASSET MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock Inc., CITADEL ADVISORS LLC, Decheng Capital LLC, STATE STREET CORP, MORGAN STANLEY, and Woodline Partners LP.
This page lists
142
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
140
Q2 2024 holders
142
Holder diff
2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.